If good b-thal data can propel the stock from the high $20s to $112 in ten months, what can a monster game changer such as SCD do for the stock? Granted, b-thal has caused some baked-in price for SCD, but your target of $150 is way too low. If the current patient on SCD therapy is functionally cured, I think we're looking at a 100% pop at a minimum. Within a year of that, who knows given the addition of CAR-T and more b-thal and SCD data. The potential gains here are massive, even at the current price.
Um, no. BLUE is not working with INO and it never will. INO is junk. BLUE, on the other hand, is the real deal. Go away, pumper.
I really hope a buyout isn't in the works, and frankly, I kind of doubt it is. I don't think the CEO has that on his mind at this point. Not until CAR-T data starts flowing in at least. I hope BLUE isn't bought out anytime soon. I'll take the longterm value over a quick gain on this one because the potential longterm gains are mind-blowing.
I think you're actually wrong, jrrt1. At least in the sense that I get the feeling that CG is aware of what is being said on message boards, twitter, etc. I distinctly remember a call from a couple of years ago (when things were generally upbeat) where CG had mentioned heckling from some message board trolls and seemed to suggest one in particular. My wager is that that person was starfe. I imagine starfe and the CEO likely know each other, or know of each other. I could be wrong. Just a gut feeling based on that comment from a couple of years back, and it lines up with starfe's fascination with the CEO.
Speaking of, where is starfe?
Doubtful they went short. More likely they cut their losses to reduce their taxes. Too much up in the air with SRPT right now. If the FDA gives the green light later this year, there will still be a ton of upside potential, even after a huge pop, and I imagine more big boys will jump on board at that point. I can't blame them for being cautious at this point given the FDA's and management's shared mishandling of this entire process.
I"m sure Pompe could be next, but a Phase 1 trial is AT LEAST one year away. So it just seems odd to use the word "surprise" here. That suggests something is coming soon.
The likelihood that at least one of the boys becomes non-ambulatory between now and 196-week data is fairly high. Unfortunately, the market will likely ignore the natural history and drop the stock if this happens. Because the market absolutely hates SRPT.
Those surprises are a long, long ways off. It's all pre-clinical still, so not terribly meaningful at this point in time.
You bought back in too soon. That gap is likely going to be filled within the next two months, unless insanely good news comes out before that can happen.
It also traded outside of the upper BB for a few days. The stock is trading in a technical pattern right now and will continue to do so in the absence of news. Nothing more. Nothing less.
The gap will get filled (unless news comes) and the stock will bounce from there.
You do realize the stock shot up to 70 on the daily RSI in just a few days, right? Precipitated by the BofA analyst's report, and a mini short squeeze. Of course, the stock is going to drop after being overbought because of these things. It's not rocket science. It has nothing to do with Chris.
This isn't going to retest 52-week lows unless dystrophin news is bad. It has broken out of a big technical trading channel. We aren't going under $12 again unless bad news arrives.
Throw enough darts and you'll eventually hit a bull's-eye. I'm glad the stock is up, but I really wish we wouldn't have gapped. I'd have preferred a steady run throughout the day. Gap ups almost always get filled, especially when the gap isn't because of substantial news, as is the case here. (Amazing dystrophin biopsies and rereads would count as substantial.) The likelihood is that this gap gets filled, unless substantial news is released before that happens. The good news is that we have likely hit the 52-week low at this point (and hopefully, the lowest we will ever be again.)
This is a short squeeze. Not a huge one, but big enough to guess that we've likely hit the bottom of our trading range at this point. (Although bad news about dystrophin could change that. Don't think that happens though.)